Clinical trial · Observational
Single Center Registration Study on HER2 Expression and Clinical Pathological Characteristics in Prostate Cancer
Single Center Registration Study on HER2 Expression and Clinical Pathological Characteristics in Prostate Cancer.
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
This study is a single center, non-interference, retrospective registration study: HER2 testing and disease information collection were conducted on patients diagnosed with prostate cancer and able to obtain tumor tissue in our hospital from January 2018 to July 2023. Statistical analysis was conducted on the collected information to analyze the expression of HER2 in Chinese prostate patients and the correlation between HER2 and disease type.
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| HER2 Expression and Clinical Pathological Characteristics in Prostate Cancer | — | UNRESOLVED | — |
Interventions
Interventions (1)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| Collect HER2 expression in prostate cancer patients | Diagnostic Test | — | UNRESOLVED |
Design
Arms and outcomes
Arms (1)
- label
- experimental group
- description
- 1. Prostate cancer patients confirmed by histopathology in our hospital from January 2018 to July 2023; 2. Men aged ≥ 18 years old; 3. The expected survival time is greater than 12 weeks; 4. The KPS functional status score is greater than 60, and the ECOG status score is 0-2 points; 5. The subjects voluntarily joined this study, signed an informed consent form, had good compliance, and cooperated with follow-up.
- interventionNames
- Diagnostic Test: Collect HER2 expression in prostate cancer patients
Primary outcomes (1)
- measure
- HER2 expression in prostate cancer patients
- timeFrame
- 18 months
- description
- HER2 test results
Secondary outcomes (2)
- measure
- Correlation between HER2 expression (IHC0/1+/2+/3+) and disease characteristics in locally advanced or metastatic prostate cancer patients
Eligibility
Eligibility (as posted)
- Sex
- Male
- Minimum age
- 50 Years
- Maximum age
- 90 Years
Show eligibility criteria text
Inclusion Criteria: * 1\. Prostate cancer patients confirmed by histopathology in our hospital from January 2018 to July 2023; 2\. Men aged ≥ 18 years old; 3\. The expected survival time is greater than 12 weeks; 4\. The KPS functional status score is greater than 60, and the ECOG status score is 0-2 points; 5\. The subjects voluntarily joined this study, signed an informed consent form, had good compliance, and cooperated with follow-up. Exclusion Criteria: \- 1. Those who have been diagnosed with tumors in other parts, such as lung cancer, liver cancer, stomach cancer, colorectal cancer, breast cancer, etc. (except for cancer in situ or non melanoma skin cancer, or combined tumors with low recurrence probability within a few years); 2\. According to the researcher's judgment, there are other patients who are not suitable for inclusion.
References
Publications (0)
Data not yet available